Total Valuation
Iradimed has a market cap or net worth of €1.05B. The enterprise value is €1.18K.
Market Cap€1.05B
Enterprise Value€1.18K
Share Statistics
Iradimed has 12,783,035 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,783,035
Owned by Insiders34.87%
Owned by Institutions1.65%
Financial Efficiency
Iradimed’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 21.02%.
Return on Equity (ROE)0.24
Return on Assets (ROA)0.21
Return on Invested Capital (ROIC)21.02%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee504.90K
Profits Per Employee135.42K
Employee Count166
Asset Turnover0.77
Inventory Turnover1.68
Valuation Ratios
The current PE Ratio of Iradimed is 51.0. Iradimed’s PEG ratio is 3.34.
PE Ratio51.0
PS Ratio14.77
PB Ratio13.08
Price to Fair Value13.08
Price to FCF72.03
Price to Operating Cash Flow42.80
PEG Ratio3.34
Income Statement
In the last 12 months, Iradimed had revenue of 83.81M and earned 22.48M in profits. Earnings per share was 1.77.
Revenue83.81M
Gross Profit64.32M
Operating Income26.15M
Pretax Income28.36M
Net Income22.48M
EBITDA30.74M
Earnings Per Share (EPS)1.77
Cash Flow
In the last 12 months, operating cash flow was 28.94M and capital expenditures -4.85M, giving a free cash flow of 24.10M billion.
Operating Cash Flow28.94M
Free Cash Flow24.10M
Free Cash Flow per Share1.89
Dividends & Yields
Iradimed pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change62.06%
50-Day Moving Average81.44
200-Day Moving Average79.42
Relative Strength Index (RSI)47.35
Average Volume (3m)0.00
Important Dates
Iradimed upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).
Last Earnings DateJul 31, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Iradimed as a current ratio of 7.98, with Debt / Equity ratio of 0.00%
Current Ratio7.98
Quick Ratio6.84
Debt to Market Cap0.00
Net Debt to EBITDA-1.66
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Iradimed has paid 5.88M in taxes.
Income Tax5.88M
Effective Tax Rate0.21
Enterprise Valuation
Iradimed EV to EBITDA ratio is 38.59, with an EV/FCF ratio of 69.05.
EV to Sales14.16
EV to EBITDA38.59
EV to Free Cash Flow69.05
EV to Operating Cash Flow47.56
Balance Sheet
Iradimed has €56.37M in cash and marketable securities with €0.00 in debt, giving a net cash position of €56.37M billion.
Cash & Marketable Securities€56.37M
Total Debt€0.00
Net Cash€56.37M
Net Cash Per Share€4.41
Tangible Book Value Per Share€7.17
Margins
Gross margin is 75.86%, with operating margin of 31.20%, and net profit margin of 26.82%.
Gross Margin75.86%
Operating Margin31.20%
Pretax Margin33.84%
Net Profit Margin26.82%
EBITDA Margin36.68%
EBIT Margin33.84%
Analyst Forecast
The average price target for Iradimed is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast6.25%
EPS Growth Forecast10.07%